Repositioning itself as an oncology-focused biotech company, Sweden-based Medivir has agreed to divest its wholly owned subsidiary Biophausia, which markets the company’s branded portfolio within the Nordic countries, to Karo Pharma for SEK908 M (US$101 M) in cash. Medivir is also to acquire two Phase II oncology candidates, remetinostat and birinapant, from US-based TetraLogic Pharmaceuticals in a deal worth upto US$238 M.